evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

35 questions · 35 findings · 1 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 15 · 42.9%GRADE not reported 0 · 0%Very low 12 · 34.3%Low 7 · 20%Moderate 1 · 2.9%High 0 · 0%

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Adverse events, · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Adverse events, · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).

1 finding from 1 review